株洲千金药业股份有限公司2025年度业绩快报公告

Financial Performance Summary - The company reported preliminary financial data for the year 2025, indicating stable revenue growth from core industrial enterprises and improved profitability [1] - The acquisition of stakes in two subsidiaries, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. (28.92% stake) and Hunan Qianjin Xieli Pharmaceutical Co., Ltd. (68% stake), contributed to the financial performance starting from October and November 2025 respectively [1] Financial Data and Indicators - The financial data for 2025 is presented in yuan, but specific numerical values are not disclosed in the announcement [1]